{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-425647","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2026-10-20T10:05:17+00:00","discovered_at":"2026-10-20T10:10:00.215289+00:00","generated_at":"2026-10-20T10:10:08.298502+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rapport's RAP-219 hits Phase 2 primary endpoint in bipolar mania (3.1-pt YMRS gain, p=0.045)","bullets":["Phase 2 met primary endpoint: 3.1-point placebo-adjusted YMRS improvement at Week 3 (p=0.045); 15.4-point mean reduction from baseline vs 12.3 on placebo.","Secondary CGI-BP mania severity improved 0.4 points vs placebo (p=0.024); all 11 YMRS items improved, with 4 reaching nominal significance.","253 adults with bipolar I mania enrolled (126 on RAP-219 0.75 mg, 127 placebo); all TEAEs mild or moderate, no SAEs; 3.2% vs 0.8% discontinued for TEAE.","Plans FDA End-of-Phase 2 meeting in Q1 2027 and two Phase 3 bipolar mania trials starting 2H 2027; FOS FOCUS 1/2 enrolling, PGTCS Phase 3 1H 2027.","$436.1M in cash, equivalents and short-term investments as of June 30, 2026; runway into 2H 2029, beyond FOS Phase 3 topline data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-425647","json":"https://secwatch.observer/filing/0001193125-26-425647.json","markdown":"https://secwatch.observer/filing/0001193125-26-425647.md","text":"https://secwatch.observer/filing/0001193125-26-425647.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/0001193125-26-425647-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-20T10:10:08.298502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}